Base de dados : MEDLINE
Pesquisa : D06.347 [Categoria DeCS]
Referências encontradas : 4939 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 494 ir para página                         

  1 / 4939 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29317219
[Au] Autor:Sun X; Deng X; Cai W; Li W; Shen Z; Jiang T; Huang J
[Ad] Endereço:Institute of Integrated Chinese and Western medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.
[Ti] Título:Icariin inhibits LPS-induced cell inflammatory response by promoting GRα nuclear translocation and upregulating GRα expression.
[So] Source:Life Sci;195:33-43, 2018 Feb 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Icariin (ICA) is a flavonoid isolated from certain plant species in the genus Epimedium, especially Epimedium brevicornum. Previous studies indicated that ICA has certain regulatory effects on some inflammatory diseases, and that ICA regulates the activity of glucocorticoid receptor (GR) and NF-κB. But the causal link between GR and NF-κB and other downstream pathways in effects of ICA remained elusive, therefore here we have investigated whether ICA could promote GR function, in turn, to regulate NF-κB and/or other factors to achieve its anti-inflammatory effect. MAIN METHODS: Inflammatory cell models were induced by lipopolysaccharide (LPS) in RAW 264.7 and HeLa cell line. Observation of GRα nuclear translocation by confocal laser scanning microscopy. GRα and inflammatory cytokines expression was detected by RT-qPCR, Western Blotting and ELISA. Co-immunoprecipitation technique was used to detect the binding of GRα to downstream transcription factors. GRα activity was blocked by GRα antagonist RU486, and GR downstream transcription factors including NF-κB, c-Jun, and Stat3 were silenced by corresponding RNA interference. KEY FINDINGS: In both inflammatory cell models, ICA decreased LPS-induced production of inflammatory cytokines (IL-6 and TNF-α). While ICA up-regulated the amount of GRα and promoted its nucleus translocation. The increased GRα in the nucleus by ICA bound more NF-κB, c-Jun, and Stat3. Blockade GRα and silence of NF-κB, c-Jun, and Stat3 expression partially abolished the anti-inflammatory effects of ICA. SIGNIFICANCE: Promoted GR function and the consequent inhibition of pro-inflammatory transcription factors contribute a main mechanism by which ICA exerts its anti-inflammatory effect.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacologia
Flavonoides/farmacologia
Inflamação/prevenção & controle
Lipopolissacarídeos/antagonistas & inibidores
Receptores de Glucocorticoides/biossíntese
Translocação Genética/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Regulação da Expressão Gênica/efeitos dos fármacos
Células HeLa
Antagonistas de Hormônios/farmacologia
Seres Humanos
Inflamação/induzido quimicamente
Inflamação/genética
Interleucina-6/biossíntese
Interleucina-6/genética
Lipopolissacarídeos/toxicidade
Camundongos
Mifepristona/farmacologia
Células RAW 264.7
Interferência de RNA/efeitos dos fármacos
Receptores de Glucocorticoides/antagonistas & inibidores
Receptores de Glucocorticoides/genética
Fator de Necrose Tumoral alfa/biossíntese
Fator de Necrose Tumoral alfa/genética
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Flavonoids); 0 (Hormone Antagonists); 0 (Interleukin-6); 0 (Lipopolysaccharides); 0 (Receptors, Glucocorticoid); 0 (Tumor Necrosis Factor-alpha); 0 (glucocorticoid receptor alpha); 320T6RNW1F (Mifepristone); VNM47R2QSQ (icariin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE


  2 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771155
[Au] Autor:Sükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoglu CS
[Ad] Endereço:Department of Obstetrics and Gynecology, Ankara University School of Medicine, Kadin Hastaliklari ve Dogum AD, 06100 Cebeci, Ankara, Turkey.
[Ti] Título:Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
[So] Source:Reprod Biomed Online;34(1):5-10, 2017 Jan.
[Is] ISSN:1472-6491
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/agonistas
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Oócitos/citologia
Síndrome de Hiperestimulação Ovariana/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estradiol/sangue
Feminino
Antagonistas de Hormônios/uso terapêutico
Seres Humanos
Infertilidade Feminina/terapia
Infertilidade Masculina/terapia
Leuprolida/administração & dosagem
Masculino
Oócitos/efeitos dos fármacos
Oogênese
Indução da Ovulação
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Risco
Injeções de Esperma Intracitoplásmicas
Pamoato de Triptorrelina/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hormone Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone); 4TI98Z838E (Estradiol); 57773-63-4 (Triptorelin Pamoate); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  3 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29199806
[Au] Autor:Sarvilinna N; Unkila-Kallio; Härkki P; Tiitinen A; Heikinheimo O
[Ti] Título:Selective progesterone receptor modulators: new possibilities for gynecologic hormone therapy.
[So] Source:Duodecim;133(1):27-33, 2017.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:Progesterone regulates several female reproductive functions. Progesterone and synthetic progestins derived from it have long been utilized in gynecology. The effects of these steroids in target cells are mediated via progesterone receptors, Progesterone receptors are also the target of action of selective progesterone receptor modulators. Of the molecules of this newer group of drugs, two are presently in clinical use. Mifepristone is used in nonsurgical abortion, in softening of the cervix before surgical abortion, and in the induction of labor in cases of intrauterine death. The indications of ulipristal acetate are postcoital contraception and treatment of uterine myomas and the resulting symptoms.
[Mh] Termos MeSH primário: Antagonistas de Hormônios/uso terapêutico
Mifepristona/uso terapêutico
Norpregnadienos/uso terapêutico
Receptores de Progesterona/efeitos dos fármacos
Saúde Reprodutiva
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Saúde da Mulher
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hormone Antagonists); 0 (Norpregnadienes); 0 (Receptors, Progesterone); 320T6RNW1F (Mifepristone); 6J5J15Q2X8 (ulipristal)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE


  4 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29061806
[Au] Autor:Yang Y; Li X; Mamouni K; Kucuk O; Wu D
[Ad] Endereço:Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
[Ti] Título:Mifepristone Has Limited Activity to Enhance the Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
[So] Source:Anticancer Res;37(11):6235-6243, 2017 11.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mifepristone has gained great interest in its potential as a novel agent against human cancers, including prostate cancer (PCa). However, recent clinical trials using mifepristone in PCa and other cancers have been disappointing. We evaluated the in vitro and in vivo activities of mifepristone, in combination with docetaxel and enzalutamide, against bone metastatic castration-resistant PCa. MATERIALS AND METHODS: The effects of mifepristone, alone or in combination with docetaxel or enzalutamide, on PCa cell viability, in vitro, were determined by the colorimetric assay. Intratibial model of C4-2-Luc tumors in athymic nude mice was used to evaluate the in vivo efficacy of mifepristone alone or in combination with docetaxel or enzalutamide. Tumor growth in mouse bone was assessed by serum prostate-specific antigen (PSA) levels and radiography. RESULTS: Although mifepristone exhibits a certain degree of synergism with docetaxel or enzalutamide in cell culture, statistical analyses showed that combination regimens fail to demonstrate effectiveness in suppressing the skeletal growth of PCa and enhancing the in vivo efficacy of docetaxel or enzalutamide in athymic nude mice (p>0.05). CONCLUSION: These results provide the first pre-clinical evidence suggesting that mifepristone may not effectively inhibit bone metastatic PCa, either as a single agent or combined with standard chemotherapy and androgen-deprivation therapy. This report may raise concerns over the clinical use of mifepristone in the management of advanced PCa.
[Mh] Termos MeSH primário: Neoplasias Ósseas/tratamento farmacológico
Mifepristona/farmacologia
Feniltioidantoína/análogos & derivados
Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico
Taxoides/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Apoptose/efeitos dos fármacos
Neoplasias Ósseas/secundário
Proliferação Celular/efeitos dos fármacos
Antagonistas de Hormônios/farmacologia
Seres Humanos
Masculino
Camundongos
Feniltioidantoína/farmacologia
Neoplasias de Próstata Resistentes à Castração/patologia
Células Tumorais Cultivadas
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Hormone Antagonists); 0 (MDV 3100); 0 (Taxoids); 15H5577CQD (docetaxel); 2010-15-3 (Phenylthiohydantoin); 320T6RNW1F (Mifepristone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE


  5 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28885368
[Au] Autor:Yang C; Wu H; Wang J; Hu M; Xing X; Bao X; Wang R
[Ad] Endereço:aDepartment of Neurosurgery bDepartment of Pathology cDepartment of Endocrinology, Key Laboratory of Endocrinology of National Health And Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan Hutong of Dongcheng District, Beijing, China.
[Ti] Título:Successful management of octreotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery: A case report and literature review.
[So] Source:Medicine (Baltimore);96(36):e8017, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Case reports concerning the value of dopamine agonists in the treatment of patients with thyrotropin-secreting pituitary adenoma (TSHoma) are limited. Herein, we present a rare case of octreotide-insensitive TSHoma responding to bromocriptine therapy. PATIENT CONCERNS: A 45-year-old Chinese man was admitted to Peking Union Medical College Hospital with marked clinical manifestations of hyperthyroidism. DIAGNOSES: Thyroid function tests demonstrated elevated concentrations of free thyroid hormones in the presence of normal thyrotropin. Magnetic resonance imaging findings showed a pituitary microadenoma on the right side of the sellar region. Based on characteristic endocrine results and neuroimaging findings, the patient was diagnosed with TSHoma. INTERVENTIONS: Most patients with TSHomas are significantly responsive to somatostatin analog treatment. However, our patient was orally administered with bromocriptine to normalize thyroid function as assessed by suppression tests conducted prior to surgery. A transsphenoidal surgery was performed by an experienced neurosurgeon for tumor removal. OUTCOMES: The pituitary lesion was totally resected. Following the operation, the results of thyroid function tests were immediately within reference limits. During the follow-up, there was no residual or recurrent tumor. LESSONS: Attention should be paid to the role of dopamine agonists such as bromocriptine and cabergoline as adjuvant therapy for TSHomas that are insensitive to traditional medical treatment by somatostatin analogs.
[Mh] Termos MeSH primário: Adenoma/terapia
Bromocriptina/uso terapêutico
Antagonistas de Hormônios/uso terapêutico
Hipófise/cirurgia
Neoplasias Hipofisárias/terapia
Tireotropina/secreção
[Mh] Termos MeSH secundário: Adenoma/diagnóstico por imagem
Adenoma/patologia
Adenoma/secreção
Antineoplásicos Hormonais/uso terapêutico
Terapia Combinada
Seres Humanos
Masculino
Meia-Idade
Octreotida/uso terapêutico
Hipófise/diagnóstico por imagem
Hipófise/patologia
Hipófise/secreção
Neoplasias Hipofisárias/diagnóstico por imagem
Neoplasias Hipofisárias/patologia
Neoplasias Hipofisárias/secreção
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Hormone Antagonists); 3A64E3G5ZO (Bromocriptine); 9002-71-5 (Thyrotropin); RWM8CCW8GP (Octreotide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008017


  6 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28689667
[Au] Autor:Ethier JL; Desautels DN; Amir E; MacKay H
[Ad] Endereço:Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: josee-lyne.ethier@uhn.ca.
[Ti] Título:Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.
[So] Source:Gynecol Oncol;147(1):158-166, 2017 Oct.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hormonal therapy (HT) is used commonly in the treatment of advanced endometrial cancer (EC). However, a 2010 Cochrane Review did not show a survival benefit for HT. Here, we quantify its effects and explore the influence of clinico-pathologic factors and hormone receptor (HR) status on overall response rates (ORR). METHODS: A systematic search of electronic databases identified publications of HT in advanced EC. Data from individual studies reporting ORR, median progression-free (PFS) or overall survival (OS) were weighted by individual study sample size and pooled in a meta-analysis. Outcomes of estrogen (ER) and progesterone receptor (PgR) subgroups were collected. Studies of first- and second-line HT were analyzed independently. Mixed studies were included if subgroup data based on previous HT exposure were provided. Meta-regression was performed to evaluate the influence of clinico-pathologic factors on outcomes. RESULTS: Thirty-nine studies were included, with seven providing subgroup data based on HR status. First-line HT was associated with a mean ORR of 21.6% and clinical benefit rate (CBR) of 36.7%. Median PFS and OS were 2.8 and 10.2months respectively. ORR was 20.4% in clinical trials and 25.3% in observational studies. Magnitude of ORR was lower in older age, adenosquamous histology and high grade. ORR was higher in ER+ (26.5%) and PgR+ (35.5%) disease, and lower in ER- (9.2%) or PgR- (12.1%) tumors. Second-line ORR was 18.5%. CBR was 35.8%, but was significantly associated with timing of stable disease assessments in first- and second-line. Meta-regression performed in mixed and second-line studies showed an association between previous HT and greater ORR (ß 0.561; p=0.024), suggesting potential confounding by indication (re-treatment of good responders to first-line HT). CONCLUSION: HT is associated with modest ORR in advanced EC, and is greatest in HR+ tumors. Response rates in second-line are likely dependent on response to previous HT.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/uso terapêutico
Neoplasias do Endométrio/tratamento farmacológico
Hormônios Gonadais/uso terapêutico
Antagonistas de Hormônios/uso terapêutico
[Mh] Termos MeSH secundário: Quimioterapia Combinada
Neoplasias do Endométrio/química
Neoplasias do Endométrio/patologia
Feminino
Seres Humanos
Moduladores Seletivos de Receptor Estrogênico/uso terapêutico
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Gonadal Hormones); 0 (Hormone Antagonists); 0 (Selective Estrogen Receptor Modulators)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE


  7 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679085
[Au] Autor:Hornstein MD
[Ad] Endereço:From the Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston.
[Ti] Título:An Oral GnRH Antagonist for Endometriosis - A New Drug for an Old Disease.
[So] Source:N Engl J Med;377(1):81-83, 2017 07 06.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Endometriose
Antagonistas de Hormônios
[Mh] Termos MeSH secundário: Feminino
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Gonadotropinas
Seres Humanos
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Gonadotropins); 0 (Hormone Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMe1706000


  8 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28662512
[Au] Autor:Dong L; Wang S; Li Y; Zhao Z; Shen Y; Liu L; Xu G; Ma C; Li S; Zhang X; Cong B
[Ad] Endereço:Department of Forensic Medicine, Basic Medical College, Hebei Medical University, Hebei Key Laboratory of Forensic Medicine, Shijiazhuang, China.
[Ti] Título:RU486 Reverses Emotional Disorders by Influencing Astrocytes and Endoplasmic Reticulum Stress in Chronic Restraint Stress Challenged Rats.
[So] Source:Cell Physiol Biochem;42(3):1098-1108, 2017.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:AIMS: To investigate the effect of RU486 (mifepristone) on emotional disorders in chronic restraint stress-induced rats and to explore the mechanisms of that phenomenon. METHODS: For this purpose, 80 healthy male Sprague Dawley rats were randomly divided into four groups: the normal group (Con group, The Con group members received no treatment, eating and drinking freely), the chronic restraint stress group (CRS group, normal Sprague Dawley rats treated with chronic restraint stress, 6 h/day for 21days), the propylene glycol group (CRS+propylene glycol) and the RU486 group (CRS+RU486). RU486 or propylene glycol was administered 30 mins before each CRS procedure. Twenty-four hours after CRS exposure, we investigated the effects of CRS on the anxiety-like behavior using an elevated plus-maze (EPM). To explore the mechanisms of RU486 on anxiety, we measured the expression of glial fibrillary acid protein (GFAP) and ß-subunit of S100 (S100ß) via immunohistochemistry and western blot analysis. Apoptosis was demonstrated by flow cytometry. In addition, endoplasmic reticulum (ER) stress markers, glucose regulated protein 78 (GRP78), C/EBP homologous protein (CHOP) and Cysteine aspartic acid specific protease-12 (Caspase-12), were detected by western blot analysis. RESULTS: Compared to the control group, rats in the CRS and propylene glycol group showed decreased exploratory behavior on the open arms during EPM testing, and these reductions were accompanied by significantly reduced GFAP and S100ß expression, increased apoptosis and GRP78, CHOP, and caspase-12 expression in the amygdala. However, RU486 increases the exploratory behavior and reverses the changes of GFAP, S100ß, GRP78, CHOP, and caspase-12 and protects cells against apoptosis. CONCLUSIONS: Taken together, these data suggest that exposure to chronic restraint stress decreases the number of astrocytes and induces apoptosis and ER stress in the amygdala, which are possible causes for psychiatric disorders. RU486 can significantly ameliorate abnormal behaviors in CRS-induced anxiety model rats. The protective effects of RU486 could be attributed to its anti-ER stress, anti-apoptosis and astrocyte increasing effects.
[Mh] Termos MeSH primário: Ansiedade/tratamento farmacológico
Astrócitos/efeitos dos fármacos
Estresse do Retículo Endoplasmático/efeitos dos fármacos
Antagonistas de Hormônios/uso terapêutico
Mifepristona/uso terapêutico
Estresse Psicológico/tratamento farmacológico
[Mh] Termos MeSH secundário: Tonsila do Cerebelo/efeitos dos fármacos
Tonsila do Cerebelo/metabolismo
Tonsila do Cerebelo/patologia
Animais
Ansiedade/metabolismo
Ansiedade/patologia
Astrócitos/metabolismo
Astrócitos/patologia
Proteína Glial Fibrilar Ácida/análise
Proteína Glial Fibrilar Ácida/metabolismo
Masculino
Ratos Sprague-Dawley
Subunidade beta da Proteína Ligante de Cálcio S100/análise
Subunidade beta da Proteína Ligante de Cálcio S100/metabolismo
Estresse Psicológico/metabolismo
Estresse Psicológico/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glial Fibrillary Acidic Protein); 0 (Hormone Antagonists); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100b protein, rat); 0 (glial fibrillary acid protein, rat); 320T6RNW1F (Mifepristone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1159/000478764


  9 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28614003
[Au] Autor:Geer EB; Shafiq I; Gordon MB; Bonert V; Ayala A; Swerdloff RS; Katznelson L; Lalazar Y; Manuylova E; Pulaski-Liebert KJ; Carmichael JD; Hannoush Z; Surampudi V; Broder MS; Cherepanov D; Eagan M; Lee J; Said Q; Neary MP; Biller BMK
[Ti] Título:BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
[So] Source:Endocr Pract;23(8):962-970, 2017 Aug.
[Is] ISSN:1530-891X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Cushing disease (CD) results from excessive exposure to glucocorticoids caused by an adrenocorticotropic hormone-secreting pituitary tumor. Inadequately treated CD is associated with significant morbidity and elevated mortality. Multicenter data on CD patients treated in routine clinical practice are needed to assess treatment outcomes in this rare disorder. The study purpose was to describe the burden of illness and treatment outcomes for CD patients. METHODS: Eight pituitary centers in four U.S. regions participated in this multicenter retrospective chart review study. Subjects were CD patients diagnosed at ≥18 years of age within the past 20 years. Descriptive statistical analyses were conducted to examine presenting signs, symptoms, comorbidities, and treatment outcomes. RESULTS: Of 230 patients, 79% were female (median age at diagnosis, 39 years; range, 18 to 78 years). Length of follow-up was 0 to 27.5 years (median, 1.9 years). Pituitary adenomas were 0 to 51 mm. The most common presenting comorbidities included hypertension (67.3%), polycystic ovary syndrome (43.5%), and hyperlipidemia (41.5%). Biochemical control was achieved with initial pituitary surgery in 41.4% patients (91 of 220), not achieved in 50.0% of patients (110 of 220), and undetermined in 8.6% of patients (19 of 220). At the end of follow-up, control had been achieved with a variety of treatment methods in 49.1% of patients (110 of 224), not achieved in 29.9% of patients (67 of 224), and undetermined in 21.0% of patients (47 of 224). CONCLUSION: Despite multiple treatments, at the end of follow-up, biochemical control was still not achieved in up to 30% of patients. These multicenter data demonstrate that in routine clinical practice, initial and long-term control is not achieved in a substantial number of patients with CD. ABBREVIATIONS: BLA = bilateral adrenalectomy CD = Cushing disease CS = Cushing syndrome eCRF = electronic case report form MRI = magnetic resonance imaging PCOS = polycystic ovary syndrome.
[Mh] Termos MeSH primário: Adenoma Hipofisário Secretor de ACT/terapia
Adenoma/terapia
Hipersecreção Hipofisária de ACTH/terapia
[Mh] Termos MeSH secundário: Inibidores de 14-alfa Desmetilase/uso terapêutico
Adenoma Hipofisário Secretor de ACT/complicações
Adenoma Hipofisário Secretor de ACT/metabolismo
Adenoma Hipofisário Secretor de ACT/patologia
Adenoma/complicações
Adenoma/metabolismo
Adenoma/patologia
Adolescente
Adrenalectomia
Adulto
Idoso
Antineoplásicos/uso terapêutico
Comorbidade
Inibidores Enzimáticos/uso terapêutico
Ergolinas/uso terapêutico
Feminino
Seguimentos
Hirsutismo/etiologia
Antagonistas de Hormônios/uso terapêutico
Hormônios/uso terapêutico
Seres Humanos
Hiperlipidemias/epidemiologia
Hipertensão/epidemiologia
Hipoglicemiantes/uso terapêutico
Cetoconazol/uso terapêutico
Masculino
Metirapona/uso terapêutico
Meia-Idade
Mifepristona/uso terapêutico
Debilidade Muscular/etiologia
Atrofia Muscular/etiologia
Procedimentos Neurocirúrgicos
Obesidade Abdominal/etiologia
Hipersecreção Hipofisária de ACTH/complicações
Hipersecreção Hipofisária de ACTH/epidemiologia
Hipersecreção Hipofisária de ACTH/metabolismo
Irradiação Hipofisária
Síndrome do Ovário Policístico/epidemiologia
Estudos Retrospectivos
Somatostatina/análogos & derivados
Somatostatina/uso terapêutico
Estrias de Distensão/etiologia
Tiazolidinedionas/uso terapêutico
Resultado do Tratamento
Carga Tumoral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (14-alpha Demethylase Inhibitors); 0 (Antineoplastic Agents); 0 (Enzyme Inhibitors); 0 (Ergolines); 0 (Hormone Antagonists); 0 (Hormones); 0 (Hypoglycemic Agents); 0 (Thiazolidinediones); 05V02F2KDG (rosiglitazone); 320T6RNW1F (Mifepristone); 51110-01-1 (Somatostatin); 98H1T17066 (pasireotide); LL60K9J05T (cabergoline); R9400W927I (Ketoconazole); ZS9KD92H6V (Metyrapone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.4158/EP171787.OR


  10 / 4939 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28520729
[Au] Autor:Vanni VS; Somigliana E; Reschini M; Pagliardini L; Marotta E; Faulisi S; Paffoni A; Vigano' P; Vegetti W; Candiani M; Papaleo E
[Ad] Endereço:Centro Scienze Natalità, IRCCS San Raffaele Scientific Institute, Milan, Italy.
[Ti] Título:Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF/ICSI cycles.
[So] Source:PLoS One;12(5):e0176482, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cycles with progesterone elevation during controlled ovarian stimulation (COS) for IVF/ICSI are commonly managed with a "freeze-all" strategy, due to a well-recognized detrimental effect of high progesterone levels on endometrial receptivity. However, also a detrimental effect of elevated progesterone on day-3 embryo quality has recently been found with regards to top quality embryo formation rate. Because blastocyst culture and cryopreservation are largely adopted, we deemed relevant to determine whether this detrimental effect is also seen on blastocyst quality on day 5-6. This issue was investigated through a large two-center retrospective study including 986 GnRH antagonist IVF/ICSI cycles and using top quality blastocyst formation rate as the main outcome. Results showed that on multivariate analysis sperm motility (p<0.01) and progesterone levels at ovulation triggering (p = 0.01) were the only two variables that significantly predicted top quality blastocyst formation rate after adjusting for relevant factors including female age, BMI, basal AMH and total dose of FSH used for COS. More specifically, progesterone levels at induction showed an inverse relation with top quality blastocyst formation (correlation coefficient B = -1.08, 95% CI -1.9 to -0.02) and ROC curve analysis identified P level >1.49 ng/ml as the best cut-off for identification of patients at risk for the absence of top quality blastocysts (AUC 0.55, p<0.01). Our study is the first to investigate the top quality blastocyst formation rate in relation to progesterone levels in IVF/ICSI cycles, showing that increasing progesterone is associated with lower rates of top quality blastocyst. Hence, the advantages of prolonging COS to maximize the number of collected oocytes might eventually be hindered by a decrease in top quality blastocysts available for transfer, if increasing progesterone levels are observed. This observation extends the results of two recent studies focused on day-3 embryos and deserves further research.
[Mh] Termos MeSH primário: Blastocisto/efeitos dos fármacos
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Técnicas de Maturação in Vitro de Oócitos/métodos
Oócitos/efeitos dos fármacos
Indução da Ovulação/métodos
Progesterona/farmacologia
Injeções de Esperma Intracitoplásmicas/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Antagonistas de Hormônios/farmacologia
Antagonistas de Hormônios/uso terapêutico
Seres Humanos
Técnicas de Maturação in Vitro de Oócitos/normas
Oócitos/citologia
Indução da Ovulação/normas
Gravidez
Progesterona/uso terapêutico
Injeções de Esperma Intracitoplásmicas/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Hormone Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone); 4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0176482



página 1 de 494 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde